Open AccessThe Roles of Dopamine Transport Inhibition and Dopamine Release Facilitation in Wake Enhancement and Rebound Hypersomnolence Induced by Dopaminergic Agents
Author(s) -
John A. Gruner,
Val R. Marcy,
YinGuo Lin,
Donna BozyczkoCoyne,
Michael J. Marino,
Maciej Gąsior
Publication year - 2009
Publication title -
sleep
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.222
H-Index - 207
eISSN - 1550-9109
pISSN - 0161-8105
DOI - 10.1093/sleep/32.11.1425
Subject(s) - nomifensine , amphetamine , dopamine , dopamine transporter , dopaminergic , pharmacology , methylphenidate , methamphetamine , mazindol , phentermine , bupropion , medicine , chemistry , endocrinology , attention deficit hyperactivity disorder , weight loss , psychiatry , smoking cessation , pathology , obesity
Rebound hypersomnolence (RHS: increased sleep following increased wake) is a limiting side-effect of many wake-promoting agents. In particular, RHS in the first few hours following wake appears to be associated with dopamine (DA)-releasing agents, e.g., amphetamine, but whether it can also be produced by DA transporter (DAT) inhibition alone is unknown. In these studies, DA-releasing and DAT-inhibiting agents and their interaction were systematically examined for their ability to increase wake and induce RHS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom